The World Health Organization (WHO) estimates that more than 2.5 billion people are at risk of dengue infections with 50–100 million cases occurring annually.One of the most important reasons for the increase in cases is most likely caused by rapid development and urbanization, which provide breeding sites for Aedes aegypti, a principal mosquito vector responsible for transmission of dengue virus (DENV).There are four dengue serotypes (DENV-1, DENV-2, DENV-3, DENV-4), which can cause illnesses in humans ranging from the self-limiting to the life-threatening dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS).
The NS1 is a highly conserved glycoprotein that is present at high concentrations in sera of dengue-infected patients during the early clinical phase of disease, and is found from Day 1 and up to Day 9 after onset of fever in sample of primary or secondary dengue-infected patients.The IgM become detectable on Day 3 to 5 of illness in case of primary dengue infection and persist for 2 to 3 months, whereas IgG appear by the fourteenth day and persist for life. Secondary infection shows that IgG rises within 1 to 2 days after onset of symptoms, simultaneously with IgM antibodies. Therefore, patients with secondary infections will have a positive IgG result, usually, but not always with a positive IgM result. Our Instachek™rapid test kits are designed based on the principle of detecting the presence of NS1 antigen and/or anti-dengue antibodies in Whole blood, serum or plasma of suspected dengue patients.